NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00353496,Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours,https://clinicaltrials.gov/study/NCT00353496,CLARINET,COMPLETED,The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.,YES,Endocrine Tumors,DRUG: lanreotide (Autogel formulation)|DRUG: Placebo,"Progression-Free Survival (PFS), Time from randomization to first documentation of disease progression, or death. Disease progression centrally assessed using Response Evaluation Criteria in Solid Tumours (RECIST) v1.0, From randomisation up to the last tumour assessment (scheduled at 96 weeks). Radiological scans were performed every 12 weeks during the first year and every 24 weeks during the second year","Percentage of Patients Alive & Without Disease Progression, Percentage of patients still ongoing (or completing at Week 96) without centrally assessed disease progression or death at Weeks 48 and 96., Week 48 & 96|Pharmacokinetic Profile of Lanreotide, Pharmacokinetic Profile of Lanreotide assessed by mean serum concentration at specified timepoints, Week 4, 12, 24, 36, 48, 72, 96|Change in the Global Health Status Quality of Life Assessment, Transformed scores from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire responses (QLQ)-C30. Questionnaire response scores range from 0 to 100. Higher scores indicate best possible Quality of Life., Week 12 to Week 96 (last visit)|Percentage of Patients With a Greater Than or Equal to 50% Decrease in Plasma Chromogranin A (CgA) Levels, Week 12 to Week 96 (last visit)|Percentage of Patients Still Alive Based on Available Overall Survival Data, Overall survival defined as the time from randomisation to death due to any cause. Subjects were followed for overall survival beyond study completion/withdrawal via annual telephone contact until the last subject completed the study., Randomisation to death or last visit, up to 321 weeks",,Ipsen,,ALL,"ADULT, OLDER_ADULT",PHASE3,264,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",2-55-52030-726|2005-004904-35,2006-06,2013-04,2013-04,2006-07-18,2015-01-15,2022-10-12,"Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, 90048, United States|University of Iowa, Iowa City, Iowa, 52242, United States|The John Hopkins Hospital, Baltimore, Maryland, 21287-4606, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 53792-5666, United States|University Hospital, Vienna, Austria|UZ Antwerpen, Antwerpen, Belgium|UCL Saint Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|Fakultni nemocnice Na, Bulovce, Prague, Czechia|Fekultni nemocnice Olomouc, Olomouc, Czechia|General faculty, Praha, Czechia|Sygehus Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Hôpital A. Paré, Boulogne Billancourt, 92100, France|Hôpital Beaujon, Clichy, 92118, France|CAC Oscar Lambret, Lille, 59020, France|Hôpital Edouard Herriot, Lyon, 69437, France|CHU la Timone, Marseille, 13385, France|Hôpital R. Debré, Reims, 51092, France|CHI Frejus St Raphael, St Raphael, 83300, France|Hôpital Rangueil, Toulouse, 31059, France|Unité de gastro enterologie IGR, Villejuif, 94805, France|Charite Hospital, Berlin, Germany|University Hospital, Erlangen, Germany|University Hospital, Lubeck, Germany|Gutenberg University Hospital, Mainz, Germany|University Hospital, Munchen, Germany|Lukas Hospital, Neuss, Germany|Global Hospital, Hyderabad, India|Tata Memorial Hospital, Mumbai, India|Centro di Refierimiento Oncologica, Aviano, Italy|Azienda Malpighi, Bologna, Italy|INSCT, Milano, Italy|University of Naples, Naples, Italy|Hospital S. Chiara, Pisa, Italy|Azienda San Giovanni Battista, Torino, Italy|UMC Gronigen, Gronigen, Netherlands|Erasmu MC, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Centrum Onkologii-Instytut im. Marii Sklodowskiej - Curie, oddzial w Gliwicach, Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej ul., Gliwice, Poland|Katedra i Klinika Endokrynologii Przemiany Materii i Chorob Wewnetrznych Uniwersytetu Medycznego w Poznaniu, Poznan, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika Chorob Wewnetrznych I Endokrynologii ul. Banacha 1 a, Warszawa, Poland|Szpital Bielanski im. Ks. Jerzego Popieluszki, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Endokrynologii Centrum Medycznego Ksztalcenia Podyplomowego, Warszawa, Poland|Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny, Ministrerstwa Spraw Wewnetrznych i Administratracji w Warzawie, Warszawa, Poland|Silesian Medical University, Zabrze, Poland|Narodny onkologicky ustav, Bratislava, Slovakia, Slovakia|Vychodoslovensky onkologicky ustav, Rastislavova, Slovakia, Slovakia|Hospital Vall d'Hebron, Barcelona, Spain|Institut Catala Oncologia, Barcelona, Spain|Hospital G. Maranon, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Nuestra Senora de la Candelaria, Tenerife, Spain|Sahlgrenska Hospital, Goteborg, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Uppsala, Sweden|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Royal Victoria Hospital, Belfast, United Kingdom|University Hospital Wales, Cardiff, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Free Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|QMC, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",
